Sanofi Pasteur

189 articles about Sanofi Pasteur

• CureVac GmbH, Sanofi Pasteur and In-Cell-Art Collaborate on a $33.1 Million Project Co-Funded by the U.S. Defense Advanced Research Projects Agency; Deal Projected to be Worth €150 Million-plus

  11/15/2011

• Sanofi Pasteur Presents New Data Confirming Fluzone(R) High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population

  10/24/2011

• Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine

  10/24/2011

• Sanofi Pasteur Starts Shipping New Intradermal Influenza Vaccine with 90 Percent Smaller Needle

  9/19/2011

• Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season

  7/18/2011

• Genticel Names Dr Didier Hoch, Former President of Sanofi Pasteur MSD, to its Supervisory Board

  7/6/2011

• Sanofi Pasteur Commends Winners of International BioGENEius Challenge

  6/24/2011

• Sanofi Pasteur opens $100M R&D centre in Canada

  6/21/2011

• Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims

  6/6/2011

• FDA Approves Sanofi Pasteur's Short Needle Flu Vaccine, Fluzone Intradermal

  5/10/2011

• Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio

  5/2/2011

• Merck & Co., Inc. and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases

  4/21/2011

• Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event

  2/23/2011

• Sanofi Pasteur's Clostridium Vaccine On Approval Fast Track

  11/10/2010

• Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine

  10/25/2010

• Following Positive Phase II Data, Sanofi Pasteur to Conduct Phase III Trials of Quadrivalent Influenza Virus Vaccine

  10/25/2010

• Sanofi Pasteur and U.S. Department of Health and Human Services Enter Into Agreement for Pandemic Vaccine Preparedness

  10/11/2010

• Sanofi Pasteur’s Patents on Cancer Drug Taxotere Invalidated; Paving the Way for Hospira, Inc. and Apotex Corp. to Start Selling Generic Versions

  9/28/2010

• Sanofi Pasteur Acquires VaxDesign for $60 Million

  9/28/2010

• Pieris Signs Broad Collaboration with Sanofi-Aventis (France) and Sanofi Pasteur to Develop Anticalin Therapeutics; Pieris Will Receive Upfront Payment of EUR 3.5 Million and Could Potentially Receive Up to EUR 44.5 Million in Future Commercial and Develo

  9/28/2010